Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль фиксированных комбинаций в современной терапии артериальной гипертензии: новое или хорошо забытое старое?
Адашева Т.В., Саморукова Е.И., Задионченко В.С., Ларичева К.А. Роль фиксированных комбинаций в современной терапии артериальной гипертензии: новое или хорошо забытое старое? Системные гипертензии. 2019; 16 (4): 33–37. DOI: 10.26442/2075082X.2019.4.190733
________________________________________________
Adasheva T.V., Samorukova E.I., Zadionchenko V.S.,
Laricheva K.A. Role of fixed combinations in modern treatment of arterial hypertension: new or well overlooked old? Systemic Hypertension.
2019; 16 (4): 33–37. DOI: 10.26442/2075082X.2019.4.190733
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье обсуждаются изменения в терапевтической тактике и алгоритмы терапии артериальной гипертензии (АГ), принятые в последних рекомендациях Европейского общества по артериальной гипертензии и Европейского общества кардиологов (ESH/ESC 2018). Анализируются причины неэффективности терапевтических стратегий: терапевтическая инерция, недостаточное использование комбинированной терапии, проблемы приверженности пациентов терапии, «сложность» применяемых терапевтических стратегий. Описаны этапы истории комбинированной терапии АГ и ренессанс терапии фиксированными комбинациями в 1990-е годы. Особое внимание уделяется трехкомпонентным фиксированным комбинациям лечения АГ. Обосновывается терапевтическая стратегия быстрого перехода к тройной антигипертензивной терапии при неэффективности двухкомпонентных схем. Приводятся последние экспертные консенсусы, метаанализы, исследования, обосновывающие основные положения повышения контроля АГ в популяции. Анализируются механизмы повышения приверженности терапии АГ. Отдельно анализируются результаты недавнего исследования по эффективности, безопасности и приверженности терапии при применении фиксированной комбинации амлодипин/индапамид/периндоприл.
Ключевые слова: артериальная гипертензия, комбинированная терапия, приверженность терапии.
Ключевые слова: артериальная гипертензия, комбинированная терапия, приверженность терапии.
________________________________________________
The article discusses therapeutic tactics changes and arterial hypertension (AH) treatment algorithms stated in latest European Society of Hypertension and European Society of Cardiology guidelines (ESH/ESC 2018). Causes of therapeutic strategies ineffectiveness are analyzed: therapeutical persistency, insufficient use of combined therapy, treatment adherence problems, and “complexity” of therapeutic strategies used. Stages of combined AH therapy history and treatment with fixed combinations renaissance in the 1990s are described. Special attention is given to triple-component fixed combination for AH treatment. Therapeutic strategy of rapid change to triple-component antihypertensive therapy in case of double-component schemes non-effectiveness is explained. The latest expert consensus, mataanalyses, and studies explaining fundamental principles of AH control increase in population are presented. Mechanisms of AH treatment adherence increase are analyzed. Results of the latest study of amlodipine/indapamide/perindopril fixed combination use effectiveness, safety, and treatment adherence are analyzed independently.
Полный текст
Список литературы
1. Chow CK, Teo KK, Rangarajan S et al. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959–68.
2. Yoon SS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief 2015; 220: 1–8.
3. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
4. Márquez PHP, Torres OH, San-José A et al. Potentially inappropriate antihypertensive prescriptions to elderly patients: results of a prospective, observational study. Drugs Aging 2017; 34: 453–66.
5. Petrák O, Zelinka T, Štrauch B et al. The analysis of 1254 consecutive patients with uncontrolled hypertension. J Hum Hypertens 2016; 30: 35–9.
6. Al-Ganmi AH, Perry L, Gholizadeh L, Alotaibi AM. Cardiovascular medication adherence among patients with cardiac disease: a systematic review. J Adv Nurs 2016; 72: 3001–14.
7. Okonofua EC, Simpson KN, Jesri A et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345–51.
8. McCallum L. Hypertension – state of the art 2017. Clin Med (Lond) 2017; 17: 338–40.
9. Corrao G, Parodi A, Nicotra F et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610–8.
10. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.
11. Weir MR, Hsueh WA, Nesbitt SD et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13: 404–12.
12. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32: 649–64.
13. Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension. Clin Drug Investig 2019; 9 (4): 385–93. https://doi.org/10.1007/s40261-019-00761-0
14. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
15. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ 2012; 15: 897–905.
2. Yoon SS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief 2015; 220: 1–8.
3. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
4. Márquez PHP, Torres OH, San-José A et al. Potentially inappropriate antihypertensive prescriptions to elderly patients: results of a prospective, observational study. Drugs Aging 2017; 34: 453–66.
5. Petrák O, Zelinka T, Štrauch B et al. The analysis of 1254 consecutive patients with uncontrolled hypertension. J Hum Hypertens 2016; 30: 35–9.
6. Al-Ganmi AH, Perry L, Gholizadeh L, Alotaibi AM. Cardiovascular medication adherence among patients with cardiac disease: a systematic review. J Adv Nurs 2016; 72: 3001–14.
7. Okonofua EC, Simpson KN, Jesri A et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345–51.
8. McCallum L. Hypertension – state of the art 2017. Clin Med (Lond) 2017; 17: 338–40.
9. Corrao G, Parodi A, Nicotra F et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610–8.
10. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.
11. Weir MR, Hsueh WA, Nesbitt SD et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13: 404–12.
12. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32: 649–64.
13. Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension. Clin Drug Investig 2019; 9 (4): 385–93. https://doi.org/10.1007/s40261-019-00761-0
14. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
15. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ 2012; 15: 897–905.
________________________________________________
1. Chow CK, Teo KK, Rangarajan S et al. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959–68.
2. Yoon SS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief 2015; 220: 1–8.
3. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
4. Márquez PHP, Torres OH, San-José A et al. Potentially inappropriate antihypertensive prescriptions to elderly patients: results of a prospective, observational study. Drugs Aging 2017; 34: 453–66.
5. Petrák O, Zelinka T, Štrauch B et al. The analysis of 1254 consecutive patients with uncontrolled hypertension. J Hum Hypertens 2016; 30: 35–9.
6. Al-Ganmi AH, Perry L, Gholizadeh L, Alotaibi AM. Cardiovascular medication adherence among patients with cardiac disease: a systematic review. J Adv Nurs 2016; 72: 3001–14.
7. Okonofua EC, Simpson KN, Jesri A et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345–51.
8. McCallum L. Hypertension – state of the art 2017. Clin Med (Lond) 2017; 17: 338–40.
9. Corrao G, Parodi A, Nicotra F et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610–8.
10. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.
11. Weir MR, Hsueh WA, Nesbitt SD et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011; 13: 404–12.
12. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32: 649–64.
13. Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension. Clin Drug Investig 2019; 9 (4): 385–93. https://doi.org/10.1007/s40261-019-00761-0
14. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
15. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ 2012; 15: 897–905.
Авторы
Т.В. Адашева*, Е.И. Саморукова, В.С. Задионченко, К.А. Ларичева
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*adashtv@mail.ru
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*adashtv@mail.ru
________________________________________________
Tatiana V. Adasheva*, Elena I. Samorukova, Vladimir S. Zadionchenko, Kristina A. Laricheva
Yevdokimov Moscow State University of Medicine and Dentistry,
Moscow, Russia
*adashtv@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.